02:03 , Feb 14, 2015 |  BC Extra  |  Company News

Intrexon acquires mucosal therapeutics play ActoGeniX

Synthetic biology company Intrexon Corp. (NYSE:XON) will acquire ActoGeniX N.V. (Zwijnaarde, Belgium) for $60 million. Intrexon will gain ActoGeniX's TopAct platform, an oral delivery technology based on living, non-pathogenic microorganisms, and a pipeline including two...
07:00 , Jul 1, 2013 |  BC Week In Review  |  Financial News

Complix completes venture financing

Complix N.V. , Diepenbeek, Belgium   Business: Autoimmune, Infectious, Cancer   Date completed: 6/26/13   Type: Venture financing   Raised: €12 million ($15.7 million)   Investors: Edmond de Rothschild Investment Partners; Gimv N.V.; Biotech Fund...
00:45 , Jun 27, 2013 |  BC Extra  |  Financial News

Complix raises EUR 12 million in series B

Complix N.V. (Diepenbeek, Belgium) raised EUR 12 million ($15.7 million) in a series B round co-led by new investors Edmond de Rothschild Investment Partners; Gimv; and Biotech Fund Flanders, which is managed by Gimv. Existing...
07:00 , Jul 6, 2009 |  BC Week In Review  |  Financial News

Pronota completes venture financing

Pronota N.V. , Zwijnaarde, Belgium   Business: Diagnostic, Pharmacogenetics   Date completed: 6/29/09   Type: Venture financing   Raised: €4.9 million ($6.9 million)   Investors: LSP-Life Sciences Partners; Gimv N.V.; Biotech Fund Flanders; KBC Private...
02:10 , Feb 12, 2009 |  BC Extra  |  Financial News

ActoGeniX raises EUR 13.5M

ActoGeniX (Ghent, Belgium) raised EUR 13.5 million ($17.4 million) in an extension of a series A round, bringing the total raised in the round to EUR 33.5 million. New investor Biovest and existing investors Gimv;...
07:00 , Oct 15, 2007 |  BioCentury  |  Finance

Ebb & Flow

Profit-taking by investors after its IPO lock-up expired may have been behind last week's share price dip for cancer and autoimmune company Synta (SNTA), which shed $2.24 (20%) to $8.76 despite announcing a potentially blockbuster...
23:30 , Jul 3, 2007 |  BC Extra  |  Top Story

Diatos raises EUR 9.4 million

Diatos (Paris, France) raised EUR 9.4 million ($12.7 million) in a series D round led by existing investors GIMV; Credit Agricole; InterWest Partners; Innoven; Sofinnova Partners; and Biotech Fund Flanders. Other existing investors AGF; NIF...
02:09 , Feb 7, 2007 |  BC Extra  |  Financial News

ActoGeniX raises EUR 8.5 million

Drug delivery company ActoGeniX (Ghent, Belgium) raised EUR 8.5 million ($11 million) in the final close of a series A round, bringing to EUR 20 million ($25.9 million) the total raised in the round. The...
08:00 , Nov 20, 2006 |  BioCentury  |  Emerging Company Profile

ActoGeniX N.V.

ActoGeniX N.V. ActoGeniX N.V. Ghent, Belgium Technology: TopAct oral protein and peptide delivery based on genetically modified lactic acid bacteria Disease focus: Gastrointestinal Clinical status: Phase I Founded: 2006 by Flanders Interuniversity Institute of Biotechnology...
00:21 , Sep 20, 2006 |  BC Extra  |  Financial News

ActoGeniX raises EUR 11.5 million

Drug delivery company ActoGeniX (Ghent, Belgium) raised EUR 11.5 million ($14.6 million) in a series A round co-led by GIMV and Life Sciences Partners. Biotech Fund Flanders also participated. ActoGeniX was spun out from Ghent...